Safety, efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemo-refractory gastric cancer treated with toripalimab, a PD-1 antibody in phase Ib/II clinical trial NCT02915432

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

Annals of Oncology

Topics

Physics

Cancer Oncology

Medicine

Internal Medicine

Gastroenterology

Show all topics

DOI

10.1093/annonc/mdz197

License

CC-BY-NC

Other Formats

PDF